Prior studies have shown that the mevalonate pathway in cancer cells can impact cell division, tumor growth, and metastatic potential (Clendening et al., 2010) (Thurnher et al., 2012) and modulate immune response and mTOR signaling (Bekkering et al., 2018). This evidence concerns the gene MTOR and cancer.